PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31360147-13 2019 In conclusion, berberine exerts its neuroprotective effect against n-STZ-induced diabetic peripheral neuropathy via modulation of pro-inflammatory cytokines (TNF alpha, IL-1beta, and IL-6), oxido-nitrosative stress, BDNF, IGF-1, PPAR-gamma, and AMPK expression to ameliorate impaired allodynia, hyperalgesia, and nerve conduction velocity during T2DM. Berberine 15-24 interleukin 1 beta Rattus norvegicus 169-177 34930229-11 2021 BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1beta and tumor necrosis factor alpha) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Berberine 0-3 interleukin 1 beta Rattus norvegicus 217-234 34600570-9 2021 Our outcomes of TNF-a, IL-1B, and MDA evaluation show a significant ameliorating effect of the Berberine (BBR) and BBR-loaded micelles in pretreated groups. Berberine 115-118 interleukin 1 beta Rattus norvegicus 23-28 34284820-7 2021 CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier. Berberine 12-21 interleukin 1 beta Rattus norvegicus 198-202 34284820-7 2021 CONCLUSION: Berberine has a protective effect on NSAID-associated small intestinal injury, the mechanism may be that berberine decreases the expression of intestinal mucosa HTR4, F2RL3, NPY, CRHR2, IL1b, VIP, AQP8, and increases the expression of NOS1, that to reduce intestinal permeability and protect intestinal mucosal barrier. Berberine 117-126 interleukin 1 beta Rattus norvegicus 198-202 33682914-9 2022 Meanwhile, berberine reversed elevated expression of cytokines interleukin-1beta and TNF-alpha in the serum and downregulated nuclear factor kappaB expression. Berberine 11-20 interleukin 1 beta Rattus norvegicus 63-80 31032997-0 2019 Berberine inhibits the interleukin-1 beta-induced inflammatory response via MAPK downregulation in rat articular chondrocytes. Berberine 0-9 interleukin 1 beta Rattus norvegicus 23-41 28068647-4 2017 Subsequently, western blot analysis revealed that berberine decreased the protein expression of IL-1beta and caspase 1 and increased Nrf2 expression in RAW 264.7 macrophages. Berberine 50-59 interleukin 1 beta Rattus norvegicus 96-104 28068647-2 2017 Our results indicate that berberine (25, 50 and 75muM) suppressed the levels of pro-inflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha)) and intracellular reactive oxygen species in MSU crystal stimulated RAW 264.7 macrophages. Berberine 26-35 interleukin 1 beta Rattus norvegicus 108-125 28068647-2 2017 Our results indicate that berberine (25, 50 and 75muM) suppressed the levels of pro-inflammatory cytokines (interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha)) and intracellular reactive oxygen species in MSU crystal stimulated RAW 264.7 macrophages. Berberine 26-35 interleukin 1 beta Rattus norvegicus 127-135 29399112-5 2018 Notably, berberine significantly suppressed the levels of tumor necrosis factor, interleukin-1beta and monocyte chemoattractant protein-1, as well as reduced the protein expression levels of nuclear factor-kappaB, Bcl-2-associated X protein and cytochrome c in DAI rats. Berberine 9-18 interleukin 1 beta Rattus norvegicus 81-98 28068647-6 2017 In addition, the paw edema, pain score, pro-inflammatory cytokines (IL-1beta and TNFalpha) and articular elastase activity were found significantly reduced in berberine (50mg/kgb wt) administered MSU crystal-induced rats. Berberine 159-168 interleukin 1 beta Rattus norvegicus 68-76 26344001-5 2015 This IL-1beta expression in OASFs is attenuated by N-acetylcysteine (NAC), inhibitors of ASK1, p38, or JNK, or treatment with berberine. Berberine 126-135 interleukin 1 beta Rattus norvegicus 5-13 26344001-0 2015 Berberine attenuates CCN2-induced IL-1beta expression and prevents cartilage degradation in a rat model of osteoarthritis. Berberine 0-9 interleukin 1 beta Rattus norvegicus 34-42 24286347-0 2014 Berberine ameliorates cartilage degeneration in interleukin-1beta-stimulated rat chondrocytes and in a rat model of osteoarthritis via Akt signalling. Berberine 0-9 interleukin 1 beta Rattus norvegicus 48-65 24286347-4 2014 Here, we assessed the effects of berberine on cartilage degeneration in interleukin-1beta (IL-1beta)-stimulated rat chondrocytes and in a rat model of OA. Berberine 33-42 interleukin 1 beta Rattus norvegicus 72-89 24286347-5 2014 The results of an MTT assay and western blotting analysis showed that berberine attenuated the inhibitory effect of IL-1beta on the cell viability and proliferating cell nuclear antigen expression in rat chondrocytes. Berberine 70-79 interleukin 1 beta Rattus norvegicus 116-124 24286347-6 2014 Furthermore, berberine activated Akt, which triggered p70S6K/S6 pathway and up-regulated the levels of aggrecan and Col II expression in IL-1beta-stimulated rat chondrocytes. Berberine 13-22 interleukin 1 beta Rattus norvegicus 137-145 24286347-8 2014 The data thus strongly suggest that berberine may ameliorate cartilage degeneration from OA by promoting cell survival and matrix production of chondrocytes, which was partly attributed to the activation of Akt in IL-1beta-stimulated articular chondrocytes and in a rat OA model. Berberine 36-45 interleukin 1 beta Rattus norvegicus 214-222 21108488-7 2011 In IL-1beta-induced rat articular chondrocytes, berberine decreased IL-1beta-induced GAG release and NO production. Berberine 48-57 interleukin 1 beta Rattus norvegicus 3-11 21108488-7 2011 In IL-1beta-induced rat articular chondrocytes, berberine decreased IL-1beta-induced GAG release and NO production. Berberine 48-57 interleukin 1 beta Rattus norvegicus 68-76 21108488-8 2011 Meanwhile, high-dose berberine exhibited an anticatabolic effect in an IL-1beta-induced rat osteoarthritis (OA) model. Berberine 21-30 interleukin 1 beta Rattus norvegicus 71-79 24803296-5 2014 The expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-17 and vascular endothelial growth factor (VEGF) were obviously reduced in the sera of berberine-treated rats (all P<0.05). Berberine 180-189 interleukin 1 beta Rattus norvegicus 60-82 24676878-7 2014 Results showed significant lower expression of IL-1beta, IL-6, TGF-beta, TNF-alpha, and ICAM-1, in berberine groups compared with the operation group. Berberine 99-108 interleukin 1 beta Rattus norvegicus 47-55 24177287-9 2013 The adjunction of berberine with verapamil improved the neurological outcome in a battery of behavioral paradigms, improved spatial memory in Morris water maze task, ameliorated the oxidative-nitrosative stress, increased acetylcholinesterase (AChE) activity, as well as improved mitochondrial complex (I, II, and IV) activity, reducing tumor necrosis factor-alpha, interleukin-1 beta and caspase-3 levels in brain tissues as compared to berberine alone group in ischemic rats. Berberine 18-27 interleukin 1 beta Rattus norvegicus 366-384